Actuant (ATU) was upgraded to overweight from sector weight at Keybanc. $32 price target. The new CEO is making positive changes and the industrial business appears to be rebounding, Keybanc said.
IberiaBank (IBKC) was upgraded to outperform from market perform at JMP Securities. $94 price target. Sabadell acquisition will add to earnings, JMP said.
Ionis Pharma (IONS) was downgraded to sell from neutral at Goldman Sachs. $25 price target. There are questions on the market viability of two products in Phase 3 trials, Goldman said.
Kimberly-Clark (KMB) was downgraded to hold from buy at Societe Generale. $144 price target. The company is facing increased price competition, Societe said.
Loxo Oncology (LOXO) was downgraded to neutral at Citigroup. The valuation is less attractive, based on a $45 price target, Citi said.
Mednax (MD) was downgraded to neutral from overweight at JPMorgan. The valuation is more attractive, based on a $69 price target, JPMorgan said.